Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Wang, Lisy, Chen, Connie, Kwok, Kenneth, Biswas, Pinaki, Shapiro, Andrea, Madsen, Ann, Wollenhaupt, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722371/
https://www.ncbi.nlm.nih.gov/pubmed/33127856
http://dx.doi.org/10.1136/rmdopen-2020-001395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722371/
https://www.ncbi.nlm.nih.gov/pubmed/33127856
http://dx.doi.org/10.1136/rmdopen-2020-001395

Ejemplares similares